Treatment of ECL cell carcinoids with octreotide LAR

Fykse, Vidar; Sandvik, Ame K.; Falkmer, Sture; Waldum, Helge L.

doi:10.1016/s0016-5085(03)81479-8

Cited by 11 publications

(29 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inhibitory actions of somatostatin have been well documented in rat and human ECL cells (Fykse et al 2004) and other neuroendocrine cells including human gastric carcinoids associated with MEN1 and ZES (Aparicio et al 2001;Ducreux et al 2000;Imtiaz et al 2000). However, since both subgroups were well matched for numbers of patients with a history of somatostatin therapy, this variable is unlikely to have affected our results.…”

Section: Discussionmentioning

confidence: 84%

Elevated Serum Ghrelin Exerts an Orexigenic Effect that May Maintain Body Mass Index in Patients with Metastatic Neuroendocrine Tumors

Wang

Ohning

et al. 2007

J Mol Neurosci

View full text Add to dashboard Cite

Recurrent insulin-induced hypoglycemia (RIIH) impairs glucose counter-regulatory function in male humans and rodents and, in the latter, diminishes neuronal activation in CNS structures that monitor metabolic homeostasis, including the lateral hypothalamic area (LHA) and dorsal vagal complex (DVC). We investigated whether habituated neuronal reactivity in CNS sensing sites to hypoglycemia is correlated with modified monocarboxylate and/or glucose uptake by using quantitative real-time RT-PCR to analyze neuronal monocarboxylate transporter (MCT2) and glucose transporter variant (GLUT and GLUT4) gene expression profiles in the microdissected LHA, ventromedial nucleus hypothalamus (VMH), and DVC after one or multiple insulin injections. Because orchidectomy (ORDX) maintains uniform glycemic responses to RIIH in male rats, we also examined whether regional gene response patterns are testes dependent. In the intact male rat DVC, MCT2, GLUT3, and GLUT4 gene expression was not altered by acute hypoglycemia but was enhanced by RIIH. MCT2 and GLUT3 mRNA levels in the ORDX rat DVC did not differ among groups, but GLUT4 transcripts were progressively increased by acute and recurrent hypoglycemia. Precedent hypoglycemia decreased or increased basal MCT2 and GLUT4 gene expression, respectively, in the intact rat LHA; LHA GLUT3 transcription was augmented by RIIH in intact rats only. Acute hypoglycemia suppressed MCT2, GLUT3, and GLUT4 gene expression in the intact rat VMH, a response that was abolished by RIIH. In ORDX rats, VMH gene transcript levels were unchanged in response to one dose of insulin but were selectively diminished during RIIH. These data demonstrate site-specific, testes-dependent effects of acute and recurrent hypoglycemia on neuronal metabolic substrate transporter gene expression in characterized rat brain metabolic sensing loci and emphasize the need to assess the impact of potential alterations in glucose and lactate uptake during RIIH on general and specialized, e.g., metabolic monitoring, functions of neurons in those sites.

show abstract

Section: Discussionmentioning

confidence: 84%

Elevated Serum Ghrelin Exerts an Orexigenic Effect that May Maintain Body Mass Index in Patients with Metastatic Neuroendocrine Tumors

Wang

Ohning

et al. 2007

J Mol Neurosci

View full text Add to dashboard Cite

show abstract

“…resection of gastrinproducing cells -or somatostatin analogue therapy for suppression of gastrin secretion, influences survival in a relatively benign disease has been discussed ambiguously. Data by Borch and co-workers suggest that this may be an overtreatment in patients with gastric NET type 1 [8,10].…”

Section: Gastric Neuroendocrine Tumour Typementioning

confidence: 99%

Diagnosis and treatment of gastric neuroendocrine tumours

Plöckinger

2007

Wien Klin Wochenschr

View full text Add to dashboard Cite

Gastric neuroendocrine tumours (NET) are rare. Clinically they are classified in tumours type 1 to 3. The histological classification is according to the WHO 2000 classification for endocrine tumours. NET type 1 occur in coincidence with chronic atrophic gastritis, as single or multiple small tumours. The prognosis of type 1 tumours is excellent, with no tumour related death reported during follow-up. NET type 2 are part of the MEN-1 syndrome. These tumours may be more aggressive and even develop metastasis. However, in most patients with MEN-1 the prognosis is due to other manifestations of the disease as duodenal or pancreatic neuroendocrine tumours. Gastric neuroendocrine tumours type 3 are sporadic tumours without relationship to other gastric pathology. They tend to occur earlier, without sex preference. These tumours may develop an aggressive course, with metastatic disease and an overall poor prognosis. Thus, aggressive surgical therapy is recommended.

show abstract

“…The number of ECLomas decreased significantly as did the ECL cell density, measured by the number of chromogranin A immunoreactive cells. Both gastrin and chromogranin A levels in plasma decreased by more than 50% [28]. Thus, both these studies indicate a positive effect on tumor development in patients with gastrin induced endocrine tumors of the gastric mucosa and suggest an antiproliferative effect exerted by the somatostatin analogs probably through decreasing the circulating levels of the trophic factor gastrin.…”

Section: Endocrine Tumors Of the Gastric Mucosamentioning

confidence: 72%

Treatment of neuroendocrine tumors with somatostatin analogs

Janson

2006

Pituitary

View full text Add to dashboard Cite

Neuroendocrine tumors constitute a group of hormone producing tumors originating from neuroendocrine cells in different organs. Most tumors have a low proliferation index measured by Ki67 and the progression of the tumor is slow. However, many patients suffer from endocrine symptoms induced by the hormones produced and released by the tumor cells. For some patients these symptoms can be life- threatening as in midgut carcinoid patients suffering from carcinoid crises with extensive flushes and hypotension or in patients with severe diarrhea induced by tumors producing vasointestinal polypeptide. In many other patients the hormone-induced symptoms interfere with the ability to carry out ordinary daily activities. The introduction of somatostatin analogs in the treatment of these hormone related symptoms has made it possible to control most of them and has added significantly to the quality of life for this group of patients. Unfortunately, the clinical inhibitory effect on tumor growth has not been very good with only 5-10% of the patients showing an objective response. However, stabilization of tumor growth may be achieved in a significant number of patients. In the future, the hope is that development of new somatostatin analogs with broader receptor-binding profiles will give us new analogs which are more efficient with regard to their antiproliferative effect. This possibility will be studied in future trials.

show abstract

Treatment of ECL cell carcinoids with octreotide LAR

Cited by 11 publications

References 0 publications

Elevated Serum Ghrelin Exerts an Orexigenic Effect that May Maintain Body Mass Index in Patients with Metastatic Neuroendocrine Tumors

Elevated Serum Ghrelin Exerts an Orexigenic Effect that May Maintain Body Mass Index in Patients with Metastatic Neuroendocrine Tumors

Diagnosis and treatment of gastric neuroendocrine tumours

Treatment of neuroendocrine tumors with somatostatin analogs

Contact Info

Product

Resources

About